CRVO
CervoMed Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
2.60
▲ 0.04 (1.56%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.55
Prev close
2.56
Day high
2.64
Day low
2.56
Volume
269.57K
Market cap
$39.61M
P/E (TTM)
—
52W range
2.13 – 10.89
Day trading desk
Gap from prior close
-0.39%
Prior close 2.56
VWAP
2.60
-0.11% from price
Relative volume
0.05×
Quiet session
Session range
8.24%
2.55 – 2.76
Position in range
24%
Near session low
ATR (14D)
0.22
8.43% of price
Prior day high
2.71
PDH
Prior day low
2.50
PDL
Bid / ask spread
—
Quote not published
Session volume
270.64K
Avg 5.71M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.03%
-2.7%
1M
-1.87%
-5.6%
3M
-15.21%
-18.3%
6M
-43.41%
-54.5%
YTD
-66.84%
-79.1%
1Y
-71.61%
-91.6%
3Y
-60.30%
-134.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRVO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
4.00M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 11, 26 | BOGER JOSHUA S Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 955.41K | $2.33M | Indirect |
| Nov 18, 25 | ELDER WILLIAM ROBERT General Counsel |
BUY | 3.50K | $29.25K | Direct |
| Nov 18, 25 | WINTON MATTHEW Officer |
BUY | 5.00K | $41.43K | Direct |
| Nov 17, 25 | GREGOIRE SYLVIE L Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.60K | $182.74K | |
| Nov 17, 25 | ALAM JOHN J Chief Executive Officer |
BUY | 21.60K | $182.74K | |
| Nov 14, 25 | GREGOIRE SYLVIE L Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 7.85K | $59.10K | |
| Nov 14, 25 | WINTON MATTHEW Officer |
BUY | 10.00K | $75.70K | Direct |
| Nov 14, 25 | ALAM JOHN J Chief Executive Officer |
BUY | 7.85K | $59.10K | |
| Nov 12, 25 | GREGOIRE SYLVIE L Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 5.55K | $40.81K | Direct |
| Nov 12, 25 | ELDER WILLIAM ROBERT General Counsel |
BUY | 3.50K | $26.04K | Direct |
| Nov 12, 25 | ALAM JOHN J Chief Executive Officer |
BUY | 5.55K | $40.81K | Direct |
| May 14, 25 | ELDER WILLIAM ROBERT General Counsel |
BUY | 4.23K | $35.81K | Direct |
| Aug 27, 24 | ELDER WILLIAM ROBERT General Counsel |
BUY | 1.00K | $18.16K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALAM JOHN J |
Chief Executive Officer | — | Purchase |
BOGER JOSHUA S |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
ELDER WILLIAM ROBERT |
General Counsel | 12.50K | Purchase |
GREGOIRE SYLVIE L |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
WINTON MATTHEW |
Officer | 15.00K | Purchase |
Fundamentals
Market cap$39.61M
Enterprise value$14.67M
Revenue (TTM)$331.30K
Gross profit$-21.50M
EBITDA—
Net income$-30.35M
EPS (TTM)$-3.21
Free cash flow$-16.29M
Total cash$24.94M
Total debt$0
Book value / share$1.70
Shares outstanding15.12M
Float9.60M
Short % of float7.83%
Dividend yield—
Beta (5Y)-4.31
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.78
PEG ratio—
Price / sales—
Price / book1.54
EV / revenue44.29
EV / EBITDA—
Gross margin0.00%
Operating margin-9406.96%
Profit margin0.00%
Return on equity-107.62%
Return on assets-60.80%
Debt / equity—
Current ratio8.57
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $21.82M | $18.80M | $8.44M | $1.34M | — | +16.1% |
| Selling, general & admin | $10.48M | $9.17M | $6.52M | $2.14M | — | +14.4% |
| Total operating expense | $28.29M | $18.23M | $7.81M | $3.48M | — | +55.2% |
| Operating income | -$28.29M | -$18.23M | -$7.81M | -$3.48M | — | -55.2% |
| Net interest income | $1.34M | $1.94M | $219.43K | $61.64K | — | -31.0% |
| Pre-tax income | -$26.97M | -$16.29M | -$2.17M | -$5.80M | — | -65.5% |
| Tax provision | — | — | — | $0 | -$443.89K | — |
| Net income | -$26.97M | -$16.29M | -$2.17M | -$5.80M | — | -65.5% |
| Net income to common | -$26.97M | -$16.29M | -$2.17M | -$5.80M | — | -65.5% |
| Basic EPS | -2.98 | -2.02 | -0.82 | -11.20 | — | -47.5% |
| Diluted EPS | -2.98 | -2.02 | -0.82 | -11.20 | — | -47.5% |
| EBIT | -$28.29M | -$18.23M | -$7.81M | -$5.80M | — | -55.2% |
| EBITDA | -$28.29M | -$18.23M | -$7.81M | -$5.80M | — | -55.2% |
| Basic shares | 9.04M | 8.07M | 2.66M | 518.14K | — | +12.0% |
| Diluted shares | 9.04M | 8.07M | 2.66M | 518.14K | — | +12.0% |
One period below is a stub at the data source — the figures were never populated. Those cells read n/r rather than $0, because zero is not what was reported.
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 stub | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.24M | $9.00M | $7.79M | $4.09M | — | -8.5% |
| Cash & short-term investments | $20.86M | $38.92M | $7.79M | $4.09M | — | -46.4% |
| Total current assets | $22.88M | $43.08M | $9.96M | $4.16M | — | -46.9% |
| Property, plant & equipment | — | — | — | — | n/r | — |
| Goodwill & intangibles | — | — | — | — | n/r | — |
| Total assets | $22.88M | $43.08M | $9.97M | $4.16M | — | -46.9% |
| Total current liabilities | $4.66M | $3.88M | $2.60M | $13.16M | — | +20.0% |
| Current debt | — | — | — | $12.41M | — | — |
| Total debt | — | — | — | $12.41M | n/r | — |
| Total liabilities | $4.66M | $3.88M | $2.60M | $37.44M | — | +20.0% |
| Retained earnings | -$97.70M | -$70.73M | -$54.44M | -$52.27M | — | -38.1% |
| Shareholder equity | $18.22M | $39.20M | $7.38M | -$33.29M | — | -53.5% |
| Working capital | $18.22M | $39.20M | $7.37M | -$9.00M | — | -53.5% |
| Net tangible assets | $18.22M | $39.20M | $7.38M | -$33.29M | — | -53.5% |
| Shares issued | 9.25M | 8.70M | 5.67M | 1.36M | — | +6.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$26.97M | -$16.29M | -$2.17M | -$5.80M | — | -65.5% |
| Depreciation & amortisation | — | — | — | $0 | $93.42K | — |
| Stock-based compensation | $1.45M | $1.41M | $407.63K | $333.83K | — | +3.1% |
| Change in working capital | $2.92M | -$440.66K | -$261.36K | $379.94K | — | +763.1% |
| Operating cash flow | -$23.45M | -$16.53M | -$7.45M | -$2.57M | — | -41.9% |
| Investing cash flow | $18.10M | -$28.66M | $0 | -$12.24M | — | +163.1% |
| Financing cash flow | $4.59M | $46.40M | $11.15M | $0 | — | -90.1% |
| Free cash flow | -$23.45M | -$16.53M | -$7.45M | -$2.57M | — | -41.9% |
| End cash position | $8.24M | $9.00M | $7.79M | $4.09M | — | -8.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $4.32M | $5.14M | $5.83M | $6.04M | $5.11M | — | -15.8% |
| Selling, general & admin | $2.36M | $2.98M | $2.51M | $2.33M | $3.27M | — | -20.8% |
| Total operating expense | $6.68M | $8.11M | $8.33M | $8.04M | $6.62M | — | -17.7% |
| Operating income | -$6.68M | -$8.11M | -$8.33M | -$8.04M | -$6.62M | — | +17.7% |
| Net interest income | $104.90K | $147.39K | $240.94K | $318.79K | $368.13K | — | -28.8% |
| Pre-tax income | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | — | +17.5% |
| Net income | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | — | +17.5% |
| Net income to common | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | — | +17.5% |
| Basic EPS | -0.64 | -0.86 | — | -0.84 | -0.84 | -0.56 | +25.6% |
| Diluted EPS | -0.64 | -0.86 | — | -0.84 | -0.84 | -0.56 | +25.6% |
| EBIT | -$6.68M | -$8.11M | -$8.33M | -$8.04M | -$6.62M | — | +17.7% |
| EBITDA | -$6.68M | -$8.11M | -$8.33M | -$8.04M | -$6.62M | — | +17.7% |
| Basic shares | 10.24M | 9.26M | — | 9.25M | 9.25M | 8.70M | +10.7% |
| Diluted shares | 10.24M | 9.26M | — | 9.25M | 9.25M | 8.70M | +10.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.46M | $7.94M | $8.24M | $9.44M | $8.32M | +182.8% |
| Cash & short-term investments | $24.94M | $12.92M | $20.86M | $27.29M | $33.53M | +93.0% |
| Total current assets | $25.99M | $15.11M | $22.88M | $30.61M | $38.08M | +72.0% |
| Total assets | $25.99M | $15.11M | $22.88M | $30.61M | $38.08M | +72.0% |
| Total current liabilities | $3.03M | $4.50M | $4.66M | $4.60M | $4.64M | -32.6% |
| Total liabilities | $3.03M | $4.50M | $4.66M | $4.60M | $4.64M | -32.6% |
| Retained earnings | -$112.23M | -$105.66M | -$97.70M | -$89.61M | -$81.88M | -6.2% |
| Shareholder equity | $22.96M | $10.62M | $18.22M | $26.01M | $33.44M | +116.3% |
| Working capital | $22.96M | $10.62M | $18.22M | $26.01M | $33.44M | +116.3% |
| Net tangible assets | $22.96M | $10.62M | $18.22M | $26.01M | $33.44M | +116.3% |
| Shares issued | 13.53M | 9.26M | 9.25M | 9.25M | 8.70M | +46.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | +17.5% |
| Stock-based compensation | $362.27K | $349.20K | $298.74K | $291.72K | $497.01K | +3.7% |
| Change in working capital | -$689.90K | -$333.27K | $1.36M | $1.19M | -$518.64K | -107.0% |
| Operating cash flow | -$6.92M | -$8.02M | -$6.58M | -$6.47M | -$6.51M | +13.7% |
| Investing cash flow | $2.53M | $7.71M | $5.37M | $7.58M | -$254.99K | -67.2% |
| Financing cash flow | $18.91M | $13.80K | $0 | $0 | $4.59M | +136,951.9% |
| Free cash flow | -$6.92M | -$8.02M | -$6.58M | -$6.47M | -$6.51M | +13.7% |
| End cash position | $22.46M | $7.94M | $8.24M | $9.44M | $8.32M | +182.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.86 | -0.64 | +25.9% |
| Mar 2026 | -0.79 | -0.86 | -8.5% |
| Dec 2025 | -0.70 | -0.88 | -25.4% |
| Sep 2025 | -0.64 | -0.84 | -31.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.57 | 4 | $50.00K | -84.5% |
| Next quarter | -0.51 | 4 | $83.33K | +854.5% |
| Current year | -2.20 | 5 | $133.33K | -96.7% |
| Next year | -1.48 | 4 | $833.33K | +525.0% |
Analyst targets & ownership
Mean target$15.40
High target$25.00
Low target$7.00
Implied upside492.31%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy0 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders26.43%
Held by institutions22.29%
Institutions holding45
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.78
-6.44% from price
SMA 20
2.72
-3.73% from price
SMA 50
3.06
-14.37% from price
SMA 100
3.31
-21.50% from price
SMA 200
4.88
-46.29% from price
EMA 12
2.72
-4.45% from price
EMA 26
2.82
-7.71% from price
EMA 50
2.99
-13.09% from price
RSI (14)
42.9
Neutral
MACD (12,26,9)
-0.10
Hist -0.00
ATR (14)
0.22
8.37% of price
Realised vol 30D
67.3%
Annualised
Bollinger upper
3.06
20, 2σ
Bollinger lower
2.38
20, 2σ
50 / 200 cross
Death
3.06 vs 4.88
Trend bias
Below 200
-46.29%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.70
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
67.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-79.0%
Peak to trough
Max drawdown 5Y
-95.8%
Peak to trough
ATR 14
0.22
8.37% of price
Beta (reported)
-4.31
5Y monthly, from filing
Short interest
Shares short
832.42K
Prior 807.56K
Change vs prior
+3.1%
Shorts adding
% of float
7.83%
Normal
% of shares out
6.15%
Against total outstanding
Days to cover
1.5
Liquid
Float
9.60M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 22, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 8, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 19, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 18, 26 | Roth Capital | MAINTAINED | Buy | Buy |
| Mar 18, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 16, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateDec 14, 2018
Last split2:3
Split dateAug 17, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-10
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-07-09
Offering Registrations
S-3 · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-15
Headlines
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 17d ago
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 19d ago
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · 19d ago
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
GlobeNewswire · 20d ago
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
GlobeNewswire · 41d ago
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod in Frontotemporal Dementia
MT Newswires · 46d ago
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
GlobeNewswire · 46d ago
CervoMed Files for Resale of Common Shares
MT Newswires · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.